Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the southern Italy cooperative oncology group

Pasquale Comella, Giuseppe Frasci, Nicola Panza, Luigi Manzione, Giuseppe De Cataldis, Riccardo Cioffi, Luigi Maiorino, Enrico Micillo, Vito Lorusso, Gaetano Di Rienzo, Gianfranco Filippelli, Alfredo Lamberti, Michele Natale, Domenico Bilancia, Gianpaolo Nicolella, Angelo Di Nota, Giuseppe Comella

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Purpose: In our previous phase II study, the cisplatin, gemcitabine, and vinorelbine (PGV) regimen produced a median survival time (MST) of approximately 1 year in advanced non-small-cell lung cancer (NSCLC) patients. The present study was aimed at comparing the MST of patients treated with this triplet regimen with the MSTs of patients receiving cisplatin and vinorelbine (PV) or cisplatin and gemcitabine (PG). Patients and Methods: From April 1997, patients with locally advanced or metastatic NSCLC, an age of ≤ 70 years, and an Eastern Cooperative Oncology Group performance status ≤ 1 were randomized to receive one of the following regimens: cisplatin 50 mg/m 2, gemcitabine 1,000 mg/m 2, and vinorelbine 25 mg/m 2 on days 1 and 8 every 3 weeks (arm A); cisplatin 100 mg/m 2 on day 1 and gemcitabine 1,000 mg/m 2 on days 1, 8, and 15 every 4 weeks (arm B); or cisplatin 120 mg/m 2 on days 1 and 29 and vinorelbine 30 mg/m 2/wk (arm C). According to the two- stage design for phase III trials, an interim analysis was planned when the first 60 patients per arm were assessable for survival. Results: The survival data of 180 NSCLC patients (stage IIIB, 76 patients; stage IV, 104 patients) were analyzed in April 1999. Overall, 128 patients had died (PGV, n = 33; PG, n = 42; and PV, n = 53). The MST of patients in the PGV, PG, and PV arms was 51, 42, and 35 weeks, respectively, and the corresponding 1-year projected survival rates were 45%, 40%, and 34%, respectively. When only patients with stage IV disease were considered, an even stronger difference was seen between PGV (MST = 47 weeks) and both PG (34 weeks) and PV (27 weeks). At multivariate Cox analysis, the estimate hazard of death for patients receiving PGV compared with those receiving PV was 0.35 (95% confidence interval, 0.16 to 0.77; P <.01). The response rates were 47% in the PGV arm, 30% in the PG arm, 25% in the PV arm. Both hematologic and nonhematologic toxicities were not substantially worse in patients who received the PGV regimen. Conclusion: The PGV regimen is associated with a substantial survival gain (MST > 3 months longer) when compared with the PV combination. Because this difference in survival met one of the early stopping rules, the accrual in the PV arm has been stopped (null hypothesis rejected). Enrollment still continues in the PGV and PG arm to ascertain whether the PGV regimen can also produce a significantly longer survival than that obtained with the PG regimen. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish
Pages (from-to)1451-1457
Number of pages7
JournalJournal of Clinical Oncology
Volume18
Issue number7
Publication statusPublished - Apr 2000

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Italy
Cisplatin
Survival
vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer : Interim analysis of a phase III trial of the southern Italy cooperative oncology group. / Comella, Pasquale; Frasci, Giuseppe; Panza, Nicola; Manzione, Luigi; De Cataldis, Giuseppe; Cioffi, Riccardo; Maiorino, Luigi; Micillo, Enrico; Lorusso, Vito; Di Rienzo, Gaetano; Filippelli, Gianfranco; Lamberti, Alfredo; Natale, Michele; Bilancia, Domenico; Nicolella, Gianpaolo; Di Nota, Angelo; Comella, Giuseppe.

In: Journal of Clinical Oncology, Vol. 18, No. 7, 04.2000, p. 1451-1457.

Research output: Contribution to journalArticle

Comella, P, Frasci, G, Panza, N, Manzione, L, De Cataldis, G, Cioffi, R, Maiorino, L, Micillo, E, Lorusso, V, Di Rienzo, G, Filippelli, G, Lamberti, A, Natale, M, Bilancia, D, Nicolella, G, Di Nota, A & Comella, G 2000, 'Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the southern Italy cooperative oncology group', Journal of Clinical Oncology, vol. 18, no. 7, pp. 1451-1457.
Comella, Pasquale ; Frasci, Giuseppe ; Panza, Nicola ; Manzione, Luigi ; De Cataldis, Giuseppe ; Cioffi, Riccardo ; Maiorino, Luigi ; Micillo, Enrico ; Lorusso, Vito ; Di Rienzo, Gaetano ; Filippelli, Gianfranco ; Lamberti, Alfredo ; Natale, Michele ; Bilancia, Domenico ; Nicolella, Gianpaolo ; Di Nota, Angelo ; Comella, Giuseppe. / Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer : Interim analysis of a phase III trial of the southern Italy cooperative oncology group. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 7. pp. 1451-1457.
@article{094f1a245f2d445eb4aa1b6f5796634f,
title = "Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the southern Italy cooperative oncology group",
abstract = "Purpose: In our previous phase II study, the cisplatin, gemcitabine, and vinorelbine (PGV) regimen produced a median survival time (MST) of approximately 1 year in advanced non-small-cell lung cancer (NSCLC) patients. The present study was aimed at comparing the MST of patients treated with this triplet regimen with the MSTs of patients receiving cisplatin and vinorelbine (PV) or cisplatin and gemcitabine (PG). Patients and Methods: From April 1997, patients with locally advanced or metastatic NSCLC, an age of ≤ 70 years, and an Eastern Cooperative Oncology Group performance status ≤ 1 were randomized to receive one of the following regimens: cisplatin 50 mg/m 2, gemcitabine 1,000 mg/m 2, and vinorelbine 25 mg/m 2 on days 1 and 8 every 3 weeks (arm A); cisplatin 100 mg/m 2 on day 1 and gemcitabine 1,000 mg/m 2 on days 1, 8, and 15 every 4 weeks (arm B); or cisplatin 120 mg/m 2 on days 1 and 29 and vinorelbine 30 mg/m 2/wk (arm C). According to the two- stage design for phase III trials, an interim analysis was planned when the first 60 patients per arm were assessable for survival. Results: The survival data of 180 NSCLC patients (stage IIIB, 76 patients; stage IV, 104 patients) were analyzed in April 1999. Overall, 128 patients had died (PGV, n = 33; PG, n = 42; and PV, n = 53). The MST of patients in the PGV, PG, and PV arms was 51, 42, and 35 weeks, respectively, and the corresponding 1-year projected survival rates were 45{\%}, 40{\%}, and 34{\%}, respectively. When only patients with stage IV disease were considered, an even stronger difference was seen between PGV (MST = 47 weeks) and both PG (34 weeks) and PV (27 weeks). At multivariate Cox analysis, the estimate hazard of death for patients receiving PGV compared with those receiving PV was 0.35 (95{\%} confidence interval, 0.16 to 0.77; P <.01). The response rates were 47{\%} in the PGV arm, 30{\%} in the PG arm, 25{\%} in the PV arm. Both hematologic and nonhematologic toxicities were not substantially worse in patients who received the PGV regimen. Conclusion: The PGV regimen is associated with a substantial survival gain (MST > 3 months longer) when compared with the PV combination. Because this difference in survival met one of the early stopping rules, the accrual in the PV arm has been stopped (null hypothesis rejected). Enrollment still continues in the PGV and PG arm to ascertain whether the PGV regimen can also produce a significantly longer survival than that obtained with the PG regimen. (C) 2000 by American Society of Clinical Oncology.",
author = "Pasquale Comella and Giuseppe Frasci and Nicola Panza and Luigi Manzione and {De Cataldis}, Giuseppe and Riccardo Cioffi and Luigi Maiorino and Enrico Micillo and Vito Lorusso and {Di Rienzo}, Gaetano and Gianfranco Filippelli and Alfredo Lamberti and Michele Natale and Domenico Bilancia and Gianpaolo Nicolella and {Di Nota}, Angelo and Giuseppe Comella",
year = "2000",
month = "4",
language = "English",
volume = "18",
pages = "1451--1457",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer

T2 - Interim analysis of a phase III trial of the southern Italy cooperative oncology group

AU - Comella, Pasquale

AU - Frasci, Giuseppe

AU - Panza, Nicola

AU - Manzione, Luigi

AU - De Cataldis, Giuseppe

AU - Cioffi, Riccardo

AU - Maiorino, Luigi

AU - Micillo, Enrico

AU - Lorusso, Vito

AU - Di Rienzo, Gaetano

AU - Filippelli, Gianfranco

AU - Lamberti, Alfredo

AU - Natale, Michele

AU - Bilancia, Domenico

AU - Nicolella, Gianpaolo

AU - Di Nota, Angelo

AU - Comella, Giuseppe

PY - 2000/4

Y1 - 2000/4

N2 - Purpose: In our previous phase II study, the cisplatin, gemcitabine, and vinorelbine (PGV) regimen produced a median survival time (MST) of approximately 1 year in advanced non-small-cell lung cancer (NSCLC) patients. The present study was aimed at comparing the MST of patients treated with this triplet regimen with the MSTs of patients receiving cisplatin and vinorelbine (PV) or cisplatin and gemcitabine (PG). Patients and Methods: From April 1997, patients with locally advanced or metastatic NSCLC, an age of ≤ 70 years, and an Eastern Cooperative Oncology Group performance status ≤ 1 were randomized to receive one of the following regimens: cisplatin 50 mg/m 2, gemcitabine 1,000 mg/m 2, and vinorelbine 25 mg/m 2 on days 1 and 8 every 3 weeks (arm A); cisplatin 100 mg/m 2 on day 1 and gemcitabine 1,000 mg/m 2 on days 1, 8, and 15 every 4 weeks (arm B); or cisplatin 120 mg/m 2 on days 1 and 29 and vinorelbine 30 mg/m 2/wk (arm C). According to the two- stage design for phase III trials, an interim analysis was planned when the first 60 patients per arm were assessable for survival. Results: The survival data of 180 NSCLC patients (stage IIIB, 76 patients; stage IV, 104 patients) were analyzed in April 1999. Overall, 128 patients had died (PGV, n = 33; PG, n = 42; and PV, n = 53). The MST of patients in the PGV, PG, and PV arms was 51, 42, and 35 weeks, respectively, and the corresponding 1-year projected survival rates were 45%, 40%, and 34%, respectively. When only patients with stage IV disease were considered, an even stronger difference was seen between PGV (MST = 47 weeks) and both PG (34 weeks) and PV (27 weeks). At multivariate Cox analysis, the estimate hazard of death for patients receiving PGV compared with those receiving PV was 0.35 (95% confidence interval, 0.16 to 0.77; P <.01). The response rates were 47% in the PGV arm, 30% in the PG arm, 25% in the PV arm. Both hematologic and nonhematologic toxicities were not substantially worse in patients who received the PGV regimen. Conclusion: The PGV regimen is associated with a substantial survival gain (MST > 3 months longer) when compared with the PV combination. Because this difference in survival met one of the early stopping rules, the accrual in the PV arm has been stopped (null hypothesis rejected). Enrollment still continues in the PGV and PG arm to ascertain whether the PGV regimen can also produce a significantly longer survival than that obtained with the PG regimen. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: In our previous phase II study, the cisplatin, gemcitabine, and vinorelbine (PGV) regimen produced a median survival time (MST) of approximately 1 year in advanced non-small-cell lung cancer (NSCLC) patients. The present study was aimed at comparing the MST of patients treated with this triplet regimen with the MSTs of patients receiving cisplatin and vinorelbine (PV) or cisplatin and gemcitabine (PG). Patients and Methods: From April 1997, patients with locally advanced or metastatic NSCLC, an age of ≤ 70 years, and an Eastern Cooperative Oncology Group performance status ≤ 1 were randomized to receive one of the following regimens: cisplatin 50 mg/m 2, gemcitabine 1,000 mg/m 2, and vinorelbine 25 mg/m 2 on days 1 and 8 every 3 weeks (arm A); cisplatin 100 mg/m 2 on day 1 and gemcitabine 1,000 mg/m 2 on days 1, 8, and 15 every 4 weeks (arm B); or cisplatin 120 mg/m 2 on days 1 and 29 and vinorelbine 30 mg/m 2/wk (arm C). According to the two- stage design for phase III trials, an interim analysis was planned when the first 60 patients per arm were assessable for survival. Results: The survival data of 180 NSCLC patients (stage IIIB, 76 patients; stage IV, 104 patients) were analyzed in April 1999. Overall, 128 patients had died (PGV, n = 33; PG, n = 42; and PV, n = 53). The MST of patients in the PGV, PG, and PV arms was 51, 42, and 35 weeks, respectively, and the corresponding 1-year projected survival rates were 45%, 40%, and 34%, respectively. When only patients with stage IV disease were considered, an even stronger difference was seen between PGV (MST = 47 weeks) and both PG (34 weeks) and PV (27 weeks). At multivariate Cox analysis, the estimate hazard of death for patients receiving PGV compared with those receiving PV was 0.35 (95% confidence interval, 0.16 to 0.77; P <.01). The response rates were 47% in the PGV arm, 30% in the PG arm, 25% in the PV arm. Both hematologic and nonhematologic toxicities were not substantially worse in patients who received the PGV regimen. Conclusion: The PGV regimen is associated with a substantial survival gain (MST > 3 months longer) when compared with the PV combination. Because this difference in survival met one of the early stopping rules, the accrual in the PV arm has been stopped (null hypothesis rejected). Enrollment still continues in the PGV and PG arm to ascertain whether the PGV regimen can also produce a significantly longer survival than that obtained with the PG regimen. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0034076846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034076846&partnerID=8YFLogxK

M3 - Article

C2 - 10735892

AN - SCOPUS:0034076846

VL - 18

SP - 1451

EP - 1457

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -